The chemokine receptor CXCR7 influences prognosis in human glioma in an IDH1-dependent manner (Q38860354)

7 September 2017

title

The chemokine receptor CXCR7 influences prognosis in human glioma in an IDH1-dependent manner (English)

1 reference

7 September 2017

Peter Birner

1 reference

7 September 2017

Andrey Tchorbanov

1 reference

7 September 2017

Sevdalin Natchev

1 reference

7 September 2017

Jochen Tuettenberg

1 reference

7 September 2017

Marin Guentchev

1 reference

7 September 2017

language of work or name

English

0 references

publication date

24 June 2015

1 reference

Journal of Clinical Pathology

7 September 2017

published in

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

7 September 2017

page(s)

830-834

1 reference

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

Mutant IDH1 inhibits PI3K/Akt signaling in human glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

The role of CXCR7 on the adhesion, proliferation and angiogenesis of endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

CXCR4 and CXCR7 have distinct functions in regulating interneuron migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

Additive effect on survival of Raf kinase inhibitor protein and signal transducer and activator of transcription 3 in high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

Antiangiogenic therapies for high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

A randomized trial of bevacizumab for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-202886

10.1136/JCLINPATH-2015-202886

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference